Kyverna Therapeutics (KYTX) Assets (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Assets came in at $257.0 million in Q1 2026, down 1.39% YoY from $260.7 million in Q1 2025, and down 12.53% on a QoQ basis from $293.8 million in Q4 2025.
Kyverna Therapeutics (KYTX) Assets (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Assets data on file, last reported at $257.0 million in Q1 2026.
- Quarterly Assets fell 1.39% year-over-year to $257.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $257.0 million (down 1.39% YoY) and the FY2025 annual result came in at $293.8 million, down 3.55% from the prior year.
- Assets retreated to $257.0 million in Q1 2026, from $293.8 million in the prior quarter.
- In the past five years, Assets ranged from a high of $390.0 million in Q1 2024 to a low of $75.2 million in Q4 2023.
- A 4-year average of $269.7 million and a median of $277.2 million in 2025 frame the typical range for Assets.
- Annual changes were most pronounced in 2024 — Assets surged 305.14% — and 2025, when it tumbled 44.82%.
- Tracing KYTX's Assets over 4 years: stood at $75.2 million in 2023, then surged by 305.14% to $304.6 million in 2024, then dropped by 3.55% to $293.8 million in 2025, then retreated by 12.53% to $257.0 million in 2026.
- The last three Assets figures came in at $257.0 million (Q1 2026), $293.8 million (Q4 2025), and $187.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 219.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 219.82 Mn |
| Mar 31, 2026 | 257.02 Mn |
| Dec 31, 2025 | 293.83 Mn |
| Sep 30, 2025 | 187.16 Mn |
| Jun 30, 2025 | 226.51 Mn |
| Mar 31, 2025 | 260.66 Mn |
| Dec 31, 2024 | 304.65 Mn |
| Sep 30, 2024 | 339.20 Mn |
| Jun 30, 2024 | 363.12 Mn |
| Mar 31, 2024 | 389.98 Mn |
| Dec 31, 2023 | 75.20 Mn |